WEST PHARMACEUTICAL SERVICES, INC. (NYSE:WST) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
On June 1, 2017, West Pharmaceutical Services, Inc. (the “Company”) announced that its Board of Directors (the “Board”) had elected Deborah Keller as its newest member. With the addition of Ms. Keller, the Board increased in size to 11 directors. On July 18, 2017, Ms. Keller was appointed to the Innovation and Technology Committee.
Item 5.07 Submission of Matters to a Vote of Security Holders.
At the 2017 Annual Meeting of Shareholders, held on May 2, 2017, our shareholders approved an annual advisory vote on executive compensation.
In light of this result and other factors considered by the Board, the Board determined, on July 18, 2017, that the Company will hold annual votes on executive compensation until the next advisory vote on the frequency of votes on executive compensation occurs. The next non-binding advisory vote regarding the frequency of votes on executive compensation is required to be held no later than the Company’s 2023 Annual Meeting of Shareholders, although an earlier vote may be held at the discretion of the Board.
Item 7.01 Regulation FD Disclosure.
On July 20, 2017, the Company issued a press release announcing that its Board has approved a fourth-quarter 2017 dividend of $0.14 per share. The dividend will be paid on November 1, 2017, to shareholders of record as of October 18, 2017.
The Company also announced that it will release second-quarter 2017 financial results before the market opens on Thursday, July 27, 2017, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.
A copy of the press release issued by the Company is attached hereto as Exhibit 99.1 and incorporated herein by reference.
The information in this report (including Exhibit 99.1) is being furnished to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.
Item 9.01Financial Statements and Exhibits.
|
(d) |
Exhibits |
|
Exhibit 99.1 |
West Pharmaceutical Services, Inc. Press Release, dated July 20, 2017. |
WEST PHARMACEUTICAL SERVICES INC ExhibitEX-99.1 2 exh991july202017pressrelea.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Investor Contact:Media Contact:Quintin LaiEmily DenneyVice President,…To view the full exhibit click here
About WEST PHARMACEUTICAL SERVICES, INC. (NYSE:WST)
West Pharmaceutical Services, Inc. (West) is a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The Company’s segments include Pharmaceutical Packaging Systems segment (Packaging Systems) and the Pharmaceutical Delivery Systems segment (Delivery Systems). Its Packaging Systems segment includes primary packaging components and systems for injectable drug delivery, other components used in syringe, intravenous and blood collection systems, and prefillable syringe components. Its Delivery Systems segment includes safety and administration systems, multi-component systems for drug containment and administration and various custom contract-manufacturing solutions.
